Boehringer Ingelheim

Drug developers are fortunate in that the pharma industry is home to many high-quality CDMOs. Votes were split amongst several companies in this category, but Boehringer Ingelheim emerged as the winner. After gaining experience from developing and launching its own biopharma products, the company created a contract services arm in 1998. Today, the CDMO business is known as Boehringer Ingelheim BioXcellence, with expertise in mammalian cell culture and microbial technologies. It has facilities in Biberach, Germany; Vienna, Austria; Shanghai, China; and Fremont, USA – with the company claiming that its Biberach site is Europe’s largest multi-product mammalian cell culture plant. The Vienna and Shanghai sites were expanded in 2021, and the company was awarded “champion” status in six categories in the 2023 CDMO Leadership Awards.